IL17A and psoriasis vulgaris: In this study, the intravenous treatment of subjects with moderate-to-severe plaque psoriasis with the anti-IL-17A antibody secukinumab was used as a model to better understand disease mechanisms and to further dissect the response to IL-17A-targeting therapies.